Like semaglutide, tirzepatide helps you lose weight by lowering blood sugar, increasing feelings of fullness, and slowing down digestion
Cardiology consultation should be considered for patients with complex cardiovascular disease when questions arise about the appropriateness of continuing GLP-1 therapy in the context of heart rate changes
2.1% (consistent with weight loss rate) No Safety Signals: No increased risk of pancreatitis, thyroid tumors, or major CV events Historic Achievement: REDEFINE-1 demonstrated that CagriSema produces the highest mean weight loss (22.7%) ever reported for an obesity pharmacotherapy in a Phase 3 trial
We offer free consultations to discuss your weight loss goals and determine if Tirzepatide is the right option for you
If survodutide reaches market before retatrutide, it could provide early real-world evidence on glucagon receptor safety, which would benefit the retatrutide review process